We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Biomarkers Identify Patients with Peripheral Ruptured Atherosclerotic Lesions

By Labmedica staff writers
Posted on 04 Aug 2008
Print article
A two-analyte biomarker set was able to discriminate between patients with peripheral ruptured atherosclerotic lesions and patients with peripheral stable plaque.

Discovered by BG Medicine (Waltham, MA, USA), a life-sciences company focused on the development of novel diagnostics, the two biomarkers, E1 and E2, were studied at the department of pathology, Cardiovascular Research Institute Maastricht (CARIM; The Netherlands) in The Netherlands. The biomarkers were able to discriminate between patients with peripheral ruptured atherosclerotic lesions and patients with peripheral stable plaque with 100% specificity and 76% sensitivity.

The biomarker set was further tested on a validation series of patients with peripheral atherosclerotic lesions, coronary artery disease, and healthy controls. Ninety-three percent of patients with an acute myocardial infarction (AMI) tested positive for the biomarkers, whereas stable angina patients tested negative. In addition, 90% of AMI patients who initially tested negative for troponin T upon hospital admission, tested positive for the biomarkers. Troponin T is currently used to diagnose a heart attack.

"These two biomarkers may allow for the development of a blood test which will be used to identify patients with ruptured peripheral atherosclerotic lesions and perhaps enable earlier detection of acute myocardial infarction where current tests often fail,” said Prof. Mat Daemen, one of the founders of ACS Biomarker and Scientific Director of CARIM. "Longitudinal studies are needed to determine the diagnostic and predictive value of the biomarker set for the identification of patients experiencing cardiovascular events or those at high risk for future events.”

The study was published in the July 2008 issue of the Journal of Clinical Investigation. BG Medicine holds the exclusive worldwide license to the biomarker discovery reported in the article.


Related Links:
BG Medicine
Cardiovascular Research Institute Maastricht
New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
H.pylori DNA Extraction Kit
Savvygen Stool NA Extraction Kit
New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate Arc System has been granted US FDA 510(k) clearance (Photo courtesy of Accelerate Diagnostics)

Automated Positive Blood Culture Sample Preparation Platform Designed to Fight Against Sepsis and AMR

Delayed administration of antibiotics to patients with bloodstream infections significantly increases the risk of morbidity and mortality. For optimal therapeutic outcomes, it is crucial to rapidly identify... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.